NASDAQ:CVKD Cadrenal Therapeutics Q4 2025 Earnings Results & Report $1.01 +0.01 (+1.30%) As of 03:25 PM Eastern This is a fair market value price provided by Massive. Learn more. Cadrenal Therapeutics beat analyst earnings expectations in its Q4 2025 results, released May 7, 2026. The company reported EPS of -$1.04 versus the -$1.51 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMay 7, 2026TimeBefore Market Opens Cadrenal Therapeutics EPS ResultsActual EPS-$1.04Consensus EPS -$1.51Beat/MissBeat by +$0.47One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersCadrenal Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCadrenal Therapeutics' Q3 2026 earnings is estimated for Monday, November 9, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) Cadrenal Therapeutics Q4 2025 Earnings FAQ Did Cadrenal Therapeutics beat earnings estimates for Q4 2025? Cadrenal Therapeutics (NASDAQ:CVKD) reported earnings of -$1.04 per share for Q4 2025, beating the consensus estimate of -$1.51. The report was announced on Thursday, May 7, 2026. When is Cadrenal Therapeutics' next earnings date? Cadrenal Therapeutics' next earnings date is estimated for Monday, November 9, 2026. MarketBeat tracks confirmed and estimated earnings dates for Cadrenal Therapeutics on the company's earnings history page. Cadrenal Therapeutics Earnings HeadlinesCadrenal Therapeutics Begins Strategic Review Following FDA Alignment On CAD-1005October 7, 2026 | rttnews.comCadrenal Therapeutics Begins Strategic Review of Orphan PortfolioOctober 7, 2026 | tipranks.comMicroscopic footage reveals immune cells destroying cancer cellsTime-lapse footage from a recent clinical study shows Natural Killer cells attacking and eliminating cancer cells - and early human data revealed up to a 63.7 percent reduction in cancer burden. One NASDAQ-listed biotech's TriKE platform is designed to keep these immune cells locked onto tumors longer. Its next-generation version, showing potential for 10 to 40 times greater potency, has just cleared an important FDA milestone.October 14 at 1:00 AM | Market Tactic (Ad)Cadrenal Therapeutics Retains Tungsten Advisors to Lead Formal Strategic Process to Maximize Value of its Orphan Thrombo-Inflammatory TherapeuticsOctober 7, 2026 | globenewswire.comCadrenal Shareholders Approve Equity Plan and Board ChangesSeptember 29, 2026 | tipranks.comCadrenal Therapeutics CEO to Present at Lytham Partners Fall 2026 Investor Conference September 21, 2026 | quiverquant.comQSee More Cadrenal Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cadrenal Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cadrenal Therapeutics and other key companies, straight to your email. Email Address About Cadrenal TherapeuticsCadrenal Therapeutics (NASDAQ:CVKD) is a clinical-stage biopharmaceutical company focused on developing therapies for patients with cardiovascular disease. The company’s lead product candidate is tecarfarin, an investigational oral anticoagulant intended for people who require long-term blood-thinning treatment, including patients with implanted mechanical heart valves and left ventricular assist devices. Tecarfarin is designed as a vitamin K antagonist and is metabolized primarily through carboxylesterase 1 rather than the cytochrome P450 pathway associated with many drug interactions involving warfarin. Cadrenal is evaluating whether this mechanism may offer a treatment alternative for patients who face challenges with existing anticoagulant therapies. Tecarfarin has not been approved for commercial use, and its safety and effectiveness remain subject to clinical development and regulatory review. Cadrenal Therapeutics was established to advance tecarfarin and related cardiovascular applications. The company is headquartered in Ponte Vedra Beach, Florida, and is led by Quang Pham, who serves as chairman and chief executive officer. Its activities are centered on research, clinical development, regulatory engagement and potential commercialization of therapies for specialized cardiovascular patient populations.View Cadrenal Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
